Report cover image

Global Osteoporosis Prescribed Drug Market Growth (Status and Outlook) 2023-2029

Publisher LP Information, Inc.
Published Jun 16, 2023
Length 85 Pages
SKU # LPI18012323

Description

Global Osteoporosis Prescribed Drug Market Growth (Status and Outlook) 2023-2029


The global Osteoporosis Prescribed Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

The most commonly used osteoporosis drugs are bisphosphonates, which account for a large market share due to their effectiveness, safety, and availability in oral and intravenous formulations. Geographically, North America dominated the osteoporosis prescription drug market due to high prevalence of osteoporosis and favorable reimbursement policies. However, Asia Pacific is expected to witness the highest growth over the forecast period owing to aging population and increasing awareness about the disease. North America dominates the osteoporosis prescription drug market due to high prevalence of osteoporosis and favorable reimbursement policies.

LPI (LP Information)' newest research report, the “Osteoporosis Prescribed Drug Industry Forecast” looks at past sales and reviews total world Osteoporosis Prescribed Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Osteoporosis Prescribed Drug sales for 2023 through 2029. With Osteoporosis Prescribed Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Osteoporosis Prescribed Drug industry.

This Insight Report provides a comprehensive analysis of the global Osteoporosis Prescribed Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Osteoporosis Prescribed Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Osteoporosis Prescribed Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Osteoporosis Prescribed Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Osteoporosis Prescribed Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Osteoporosis Prescribed Drug market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Antiresorptive Drugs
Anabolic Drugs

Segmentation by application
Hospital
Clinic
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Eli Lilly
Novartis
Pfizer
Amgen
Merck
Novo nordisk
Actavis
Roche

Please note: The report will take approximately 2 business days to prepare and deliver.

Table of Contents

85 Pages
*This is a tentative TOC and the final deliverable is subject to change.*
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Osteoporosis Prescribed Drug Market Size 2018-2029
2.1.2 Osteoporosis Prescribed Drug Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Osteoporosis Prescribed Drug Segment by Type
2.2.1 Antiresorptive Drugs
2.2.2 Anabolic Drugs
2.3 Osteoporosis Prescribed Drug Market Size by Type
2.3.1 Osteoporosis Prescribed Drug Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Osteoporosis Prescribed Drug Market Size Market Share by Type (2018-2023)
2.4 Osteoporosis Prescribed Drug Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Osteoporosis Prescribed Drug Market Size by Application
2.5.1 Osteoporosis Prescribed Drug Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Osteoporosis Prescribed Drug Market Size Market Share by Application (2018-2023)
3 Osteoporosis Prescribed Drug Market Size by Player
3.1 Osteoporosis Prescribed Drug Market Size Market Share by Players
3.1.1 Global Osteoporosis Prescribed Drug Revenue by Players (2018-2023)
3.1.2 Global Osteoporosis Prescribed Drug Revenue Market Share by Players (2018-2023)
3.2 Global Osteoporosis Prescribed Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Osteoporosis Prescribed Drug by Regions
4.1 Osteoporosis Prescribed Drug Market Size by Regions (2018-2023)
4.2 Americas Osteoporosis Prescribed Drug Market Size Growth (2018-2023)
4.3 APAC Osteoporosis Prescribed Drug Market Size Growth (2018-2023)
4.4 Europe Osteoporosis Prescribed Drug Market Size Growth (2018-2023)
4.5 Middle East & Africa Osteoporosis Prescribed Drug Market Size Growth (2018-2023)
5 Americas
5.1 Americas Osteoporosis Prescribed Drug Market Size by Country (2018-2023)
5.2 Americas Osteoporosis Prescribed Drug Market Size by Type (2018-2023)
5.3 Americas Osteoporosis Prescribed Drug Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Osteoporosis Prescribed Drug Market Size by Region (2018-2023)
6.2 APAC Osteoporosis Prescribed Drug Market Size by Type (2018-2023)
6.3 APAC Osteoporosis Prescribed Drug Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Osteoporosis Prescribed Drug by Country (2018-2023)
7.2 Europe Osteoporosis Prescribed Drug Market Size by Type (2018-2023)
7.3 Europe Osteoporosis Prescribed Drug Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Osteoporosis Prescribed Drug by Region (2018-2023)
8.2 Middle East & Africa Osteoporosis Prescribed Drug Market Size by Type (2018-2023)
8.3 Middle East & Africa Osteoporosis Prescribed Drug Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Osteoporosis Prescribed Drug Market Forecast
10.1 Global Osteoporosis Prescribed Drug Forecast by Regions (2024-2029)
10.1.1 Global Osteoporosis Prescribed Drug Forecast by Regions (2024-2029)
10.1.2 Americas Osteoporosis Prescribed Drug Forecast
10.1.3 APAC Osteoporosis Prescribed Drug Forecast
10.1.4 Europe Osteoporosis Prescribed Drug Forecast
10.1.5 Middle East & Africa Osteoporosis Prescribed Drug Forecast
10.2 Americas Osteoporosis Prescribed Drug Forecast by Country (2024-2029)
10.2.1 United States Osteoporosis Prescribed Drug Market Forecast
10.2.2 Canada Osteoporosis Prescribed Drug Market Forecast
10.2.3 Mexico Osteoporosis Prescribed Drug Market Forecast
10.2.4 Brazil Osteoporosis Prescribed Drug Market Forecast
10.3 APAC Osteoporosis Prescribed Drug Forecast by Region (2024-2029)
10.3.1 China Osteoporosis Prescribed Drug Market Forecast
10.3.2 Japan Osteoporosis Prescribed Drug Market Forecast
10.3.3 Korea Osteoporosis Prescribed Drug Market Forecast
10.3.4 Southeast Asia Osteoporosis Prescribed Drug Market Forecast
10.3.5 India Osteoporosis Prescribed Drug Market Forecast
10.3.6 Australia Osteoporosis Prescribed Drug Market Forecast
10.4 Europe Osteoporosis Prescribed Drug Forecast by Country (2024-2029)
10.4.1 Germany Osteoporosis Prescribed Drug Market Forecast
10.4.2 France Osteoporosis Prescribed Drug Market Forecast
10.4.3 UK Osteoporosis Prescribed Drug Market Forecast
10.4.4 Italy Osteoporosis Prescribed Drug Market Forecast
10.4.5 Russia Osteoporosis Prescribed Drug Market Forecast
10.5 Middle East & Africa Osteoporosis Prescribed Drug Forecast by Region (2024-2029)
10.5.1 Egypt Osteoporosis Prescribed Drug Market Forecast
10.5.2 South Africa Osteoporosis Prescribed Drug Market Forecast
10.5.3 Israel Osteoporosis Prescribed Drug Market Forecast
10.5.4 Turkey Osteoporosis Prescribed Drug Market Forecast
10.5.5 GCC Countries Osteoporosis Prescribed Drug Market Forecast
10.6 Global Osteoporosis Prescribed Drug Forecast by Type (2024-2029)
10.7 Global Osteoporosis Prescribed Drug Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Eli Lilly
11.1.1 Eli Lilly Company Information
11.1.2 Eli Lilly Osteoporosis Prescribed Drug Product Offered
11.1.3 Eli Lilly Osteoporosis Prescribed Drug Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Eli Lilly Main Business Overview
11.1.5 Eli Lilly Latest Developments
11.2 Novartis
11.2.1 Novartis Company Information
11.2.2 Novartis Osteoporosis Prescribed Drug Product Offered
11.2.3 Novartis Osteoporosis Prescribed Drug Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Novartis Main Business Overview
11.2.5 Novartis Latest Developments
11.3 Pfizer
11.3.1 Pfizer Company Information
11.3.2 Pfizer Osteoporosis Prescribed Drug Product Offered
11.3.3 Pfizer Osteoporosis Prescribed Drug Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Pfizer Main Business Overview
11.3.5 Pfizer Latest Developments
11.4 Amgen
11.4.1 Amgen Company Information
11.4.2 Amgen Osteoporosis Prescribed Drug Product Offered
11.4.3 Amgen Osteoporosis Prescribed Drug Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Amgen Main Business Overview
11.4.5 Amgen Latest Developments
11.5 Merck
11.5.1 Merck Company Information
11.5.2 Merck Osteoporosis Prescribed Drug Product Offered
11.5.3 Merck Osteoporosis Prescribed Drug Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Merck Main Business Overview
11.5.5 Merck Latest Developments
11.6 Novo nordisk
11.6.1 Novo nordisk Company Information
11.6.2 Novo nordisk Osteoporosis Prescribed Drug Product Offered
11.6.3 Novo nordisk Osteoporosis Prescribed Drug Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Novo nordisk Main Business Overview
11.6.5 Novo nordisk Latest Developments
11.7 Actavis
11.7.1 Actavis Company Information
11.7.2 Actavis Osteoporosis Prescribed Drug Product Offered
11.7.3 Actavis Osteoporosis Prescribed Drug Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Actavis Main Business Overview
11.7.5 Actavis Latest Developments
11.8 Roche
11.8.1 Roche Company Information
11.8.2 Roche Osteoporosis Prescribed Drug Product Offered
11.8.3 Roche Osteoporosis Prescribed Drug Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Roche Main Business Overview
11.8.5 Roche Latest Developments
12 Research Findings and Conclusion

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us